Dobumin12.5 mg/ml

Dobumin is a synthetic catecholamine used as an intravenous inotropic agent. Its evidence-based uses are:

Established / FDA-approved use

• Short-term treatment of cardiac decompensation due to depressed myocardial contractility, arising from organic heart disease (e.g. decompensated heart failure) or following cardiac surgery.

Guideline-supported / adjunct uses

• Cardiogenic shock and low-cardiac-output states, typically as an adjunct alongside fluid resuscitation, vasopressors, and treatment of the underlying cause, under intensive/critical care monitoring.
• In atrial fibrillation with rapid ventricular response, a digitalis preparation should be given before starting Dobumin because it can enhance atrioventricular conduction.

Off-label / diagnostic use (commonly used, label-recognized in practice)

• Pharmacologic stress testing (Dobumin stress echocardiography) in patients who cannot exercise adequately, to evaluate for coronary artery disease or myocardial viability. This is a widely used, well-established off-label application performed under continuous cardiac monitoring.

Dobumin is not indicated for chronic oral or long-term outpatient use; it is administered by continuous intravenous infusion in a monitored setting.

Each mL of Dobutamine injection concentrate typically contains Dobutamine hydrochloride equivalent to 12.5 mg of Dobutamine base, supplied in single-dose vials (commonly 20 mL vials providing 250 mg Dobutamine per vial) for dilution before intravenous infusion. Strength and pack size may vary by manufacturer.

Dobumin is a synthetic catecholamine that acts predominantly as a direct-acting beta-1 adrenergic receptor agonist, with mild beta-2 and alpha-1 activity. It is administered only as a sterile intravenous infusion for the short-term support of cardiac output in patients with cardiac decompensation or cardiogenic shock.

Unlike dopamine, Dobumin does not act by releasing endogenous norepinephrine, and it has minimal effect on peripheral dopaminergic receptors. It is used exclusively in hospital settings such as intensive care units and cardiac care units, under continuous hemodynamic monitoring.

Dobutamine directly stimulates cardiac beta-1 adrenergic receptors, producing a positive inotropic effect (increased myocardial contractility and stroke volume) with only a modest increase in heart rate at usual doses. It has relatively mild chronotropic, vasodilatory (via beta-2 effects), and mild alpha-1 mediated vasoconstrictive actions, the net hemodynamic effect being increased cardiac output with a variable, generally small effect on peripheral vascular resistance and blood pressure.

Onset of action occurs within 1-2 minutes, with peak effect typically reached in about 10 minutes. The plasma half-life of Dobutamine is approximately 2 minutes. It is rapidly metabolized in the liver and other tissues via methylation and glucuronide conjugation, and metabolites are excreted mainly in the urine.

Dobumin is administered strictly by continuous intravenous infusion via an infusion pump after dilution in a compatible IV fluid; it must not be given as an IV bolus, intramuscular, or oral dose. Administer through a dedicated line where possible and monitor the infusion site for signs of extravasation or phlebitis.

• Beta-blockers (e.g. propranolol, metoprolol): may blunt or antagonize the inotropic/chronotropic effect of Dobumin, and unopposed alpha-adrenergic activity may lead to increased peripheral vascular resistance.
• Sodium nitroprusside: concurrent use with Dobumin generally produces higher cardiac output and lower pulmonary capillary wedge pressure than either agent alone; combination requires careful hemodynamic monitoring.
• Other sympathomimetics, MAO inhibitors, or agents that sensitize the myocardium to catecholamines (e.g. halogenated general anesthetics such as halothane, cyclopropane): may increase the risk of arrhythmias when combined with Dobumin.
• No clinically significant interaction has been demonstrated between Dobumin and digoxin, furosemide, spironolactone, lidocaine, nitroglycerin, morphine, atropine, heparin, potassium chloride, or acetaminophen when used concurrently.

The most common adverse effects of Dobumin are cardiovascular and dose-related.

• Common: Increased heart rate, increased systolic blood pressure, palpitations, nausea, headache, anginal or chest pain, shortness of breath.
• Cardiac: Ventricular ectopic beats (in about 5% of patients), marked tachycardia, and rarely ventricular tachycardia or other arrhythmias; precipitous drops in blood pressure have also been reported, usually reversible with dose reduction.
• Local: Phlebitis at the infusion site; rare cutaneous necrosis with extravasation.
• Other: Mild reduction in serum potassium; occasional hypersensitivity-type reactions (rash, fever, eosinophilia, bronchospasm), related in part to the sodium metabisulfite contained in some formulations, particularly in patients with asthma or sulfite sensitivity.

Pregnancy: Animal reproduction studies have not shown evidence of fetal harm, but there are no adequate and well-controlled studies in pregnant women. Dobumin should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; use only under close physician supervision.

Lactation: It is not known whether Dobumin is excreted in human breast milk. Because Dobumin is used only for short-term, closely monitored hospital administration, breastfeeding is generally interrupted during and immediately after treatment; consult a physician regarding resuming breastfeeding.

• Dobumin may cause marked increases in heart rate or blood pressure; continuous ECG and blood pressure monitoring is required throughout the infusion, and the dose should be reduced or the infusion stopped if excessive changes occur.
• Use with caution in atrial fibrillation, since Dobumin can accelerate atrioventricular conduction and increase ventricular response rate; digitalization is recommended first if rapid ventricular response is present.
• Use with caution following acute myocardial infarction, as Dobumin increases myocardial oxygen demand and may worsen ischemia or precipitate arrhythmias.
• In patients with hypovolemia, correct volume depletion with appropriate fluid replacement before starting Dobumin, as severe hypotension may otherwise occur or worsen.
• Contraindicated in idiopathic hypertrophic subaortic stenosis (see Contraindications).
• Formulations containing sodium metabisulfite may provoke allergic-type reactions, including anaphylaxis, in susceptible individuals, particularly asthmatics.
• Dobumin is for short-term use only, administered by continuous IV infusion in a setting equipped for continuous hemodynamic and cardiac rhythm monitoring.

Overdose or excessively rapid infusion of Dobumin can cause excessive cardiac stimulation, including anorexia, nausea, tremor, anxiety, palpitations, headache, dyspnea, chest pain, hypertension, tachyarrhythmias, myocardial ischemia, and ventricular fibrillation.

If overdose or a serious reaction is suspected, stop the infusion immediately and seek emergency medical attention or contact a poison control center without delay. Management is supportive: securing the airway and oxygenation, reducing or discontinuing the infusion, and treating severe ventricular arrhythmias or hypertension under medical supervision; do not attempt home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Diluted infusion solutions should be used as directed by the treating facility's protocol and discarded appropriately.

• Pediatric patients: Safety and effectiveness of Dobumin have not been formally established; use in neonates/children is limited to specialist, closely monitored intensive-care settings (see Pediatric Use).
• Elderly patients: May show a reduced hemodynamic response to Dobumin due to age-related changes in adrenergic receptor sensitivity; titrate carefully and monitor closely.
• Renal impairment: No specific dose adjustment is established; monitor hemodynamic and clinical response closely.
• Hepatic impairment: No specific dose adjustment is established; use with caution and close monitoring, as Dobumin is metabolized in the liver and other tissues.

Dobumin is intended for short-term use only, typically continued for hours to a few days while hemodynamic instability is present, under continuous monitoring in an intensive or coronary care setting; it is not intended for chronic or outpatient administration. Duration should be individualized and infusion tapered/discontinued as the patient's cardiac status stabilizes, under physician guidance.

Dobumin injection concentrate is supplied as a single-dose vial and must be diluted before use — it must be added to at least 50 mL of a compatible intravenous fluid (such as 5% Dextrose Injection, 0.9% Sodium Chloride Injection, or Lactated Ringer's Injection) to produce the final infusion concentration before administration. Diluted solutions should generally be used within 24 hours; do not administer if particulate matter or discoloration is observed. Follow the diluent manufacturer's compatibility and stability information.

Cardiac stimulant; inotropic agent; synthetic catecholamine; beta-1 adrenergic receptor agonist.

Dobutamine directly stimulates cardiac beta-1 adrenergic receptors, increasing myocardial contractility (positive inotropic effect) and cardiac output, with comparatively modest effects on heart rate and peripheral vascular resistance compared with other catecholamines. It does not act by releasing endogenous norepinephrine.

B

The safety and effectiveness of Dobumin in pediatric patients have not been formally established in controlled trials. Nonetheless, Dobumin is used off-label in neonatal and pediatric intensive care/cardiac care settings for cardiac decompensation and shock, using weight-based (mcg/kg/min) infusion dosing similar in principle to adult dosing, individualized to the patient's hemodynamic response and administered only under close specialist supervision with continuous cardiac monitoring.